Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

NCT03861403 is registered in ClinicalTrials.gov with Leap Therapeutics, Inc. as lead sponsor.

NCT NCT03861403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03861403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Lead sponsor
Leap Therapeutics, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
May 20, 2019
Completion date
July 14, 2020
Enrollment
10 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hormone receptor positive/endocrine refractory breast cancer, advanced metastatic castration-resistant prostate cancer, advanced platinum-resistant ovarian cancer, advanced triple negative breast cancer, solid tumors